Immuno-oncology

Harnessing the immune system to battle cancer

Immuno-oncology (IO) research is a rapidly evolving field that focuses on harnessing the body's immune system to fight cancer. IO aims to enhance or manipulate the immune system’s natural ability to recognise and destroy cancer cells. Through innovative approaches such as immune checkpoint inhibitors, cancer vaccines and adoptive cell therapies, IO research holds great promise for improving patient outcomes, offering more targeted, less toxic treatments and providing new hope for individuals with difficult-to-treat cancers.

Image showcasing antibody binding to human cell receptors

Immuno-oncology solutions

Nuvisan offers a broad portfolio and customised services to drive your immuno-oncology project forward. With our extensive industry experience, we advise on and perform studies that are ideally suited to advance your immuno-oncology program from the exploratory to the preclinical and clinical phases.

In vitro immuno-oncology solutions

We offer tailored cell-based screening assays for novel immunotherapeutics, mechanism of action characterisation and the identification of new drug targets. Our team of experts provides guidance on the optimal strategy for advancing your compound from the lab to clinical application. Our services include:

Access to fresh human blood panel
Immune cell mediated tumor killing assays
- Natural killer (NK) cell tumor killing assays
- Cytotoxic T cell-mediated tumor killing assays (2D and 3D)
- Antibody-dependent cytotoxicity assays with macrophages, NK or T cells
T- cell exhaustion assays
Differentiation and stimulation assays
- Tregs, Th17, Th1
- Dendritic cells
- B cell class switch
- M1/ M2 macrophages
Migration, chemotaxis and phagocytosis assays
Tumor cell line assays
- CRISPR-based screening, transcriptomics
- Target expression analysis.

LEARN MORE

In vivo immuno-oncology solutions

We provide a robust portfolio of well-characterised cell line-derived syngeneic immuno-oncology models. These models are available with the option for in-depth analysis of key immune cell subsets, allowing for correlation with tumor progression. We also offer humanised models as a platform for evaluating the efficacy of therapies in human-like systems.

Anti-tumor efficacy studies (including tolerability and exposure studies)
Pharmacokinetic (PK) and pharmacodynamic (PD) assessments
Humanised mouse models
Cytokine and immuno-profiling employing spectral flow cytometry (>28 parameters)
In vivo imaging (bioluminescence, µCT)
Single-cell RNA sequencing
Spatial profiling of tumor-infiltrating lymphocytes
- Single and multi-color fluorescent and chromogenic staining
- In situ hybridisation (RNAscope®).